nct_id,title,phase,status,study_type,conditions,interventions,molecular_targets,sponsor,collaborators,enrollment_count,start_date,completion_date,locations,needs_review,source_url
NCT00068003,Cell Harvest and Preparation for Surgery Branch Treatment Protocols,,Enrolling by invitation,Observational,Melanoma; Gastrointestinal Cancer; Metastatic Cancer; Breast Cancer; Non-Small Cell Lung Cancer,Anti-CD19 CAR PBL,,National Cancer Institute (NCI),,7000,2003-09-08,,United States,No,https://clinicaltrials.gov/study/NCT00068003
NCT01638676,A Phase I/II Trial of Vemurafenib and Metformin to Unresectable Stage IIIC and Stage IV BRAF.V600E+ Melanoma Patients,Phase 1/Phase 2,Recruiting,Interventional,Melanoma,Vemurafenib; Metformin,,University of Louisville,James Graham Brown Cancer Center,55,2012-07-05,2027-06-05,United States,No,https://clinicaltrials.gov/study/NCT01638676
NCT01776905,In Vivo Real-time Detection of Circulating Melanoma Cells,,Recruiting,Observational,Melanoma,,,University of Arkansas,,75,2013-02-05,2026-07-05,United States,No,https://clinicaltrials.gov/study/NCT01776905
NCT02012699,Integrated Cancer Repository for Cancer Research,,Recruiting,Observational,Pancreatic Cancer; Thyroid Cancer; Lung Cancer; Esophageal Cancer; Thymus Cancer; Colon Cancer; Rectal Cancer; Gastrointestinal Stromal Tumors; Anal Cancer; Bile Duct Cancer; Duodenal Cancer; Gallbladder Cancer; Gastric Cancer; Liver Cancer; Small Intestine Cancer; Peritoneal Surface Malignancies; Familial Adenomatous Polyposis; Lynch Syndrome; Bladder Cancer; Kidney Cancer; Penile Cancer; Prostate Cancer; Testicular Cancer; Ureter Cancer; Urethral Cancer; Hypopharyngeal Cancer; Laryngeal Cancer; Lip Cancer; Oral Cavity Cancer; Nasopharyngeal Cancer; Oropharyngeal Cancer; Paranasal Sinus Cancer; Nasal Cavity Cancer; Salivary Gland Cancer; Skin Cancer; Central Nervous System Tumor; Central Nervous System Cancer; Mesothelioma; Breast Cancer; Leukemia; Melanoma; Sarcoma; Unknown Primary Tumor; Multiple Myeloma; Ovarian Cancer; Endometrial Cancer; Vaginal Cancer; Neuroendocrine Tumors; Plasma Cell Dyscrasia; Healthy Control,,,University of Nebraska,,999999,2013-11-01,2099-12-05,United States,No,https://clinicaltrials.gov/study/NCT02012699
NCT02279004,A Prospective Study of Plasma Genotyping as a Noninvasive Biomarker for Genotype-directed Cancer Care,,Recruiting,Observational,NSCLC; Melanoma,,,Dana-Farber Cancer Institute,Damon Runyon Cancer Research Foundation,840,2014-07-03,2026-12-05,United States,No,https://clinicaltrials.gov/study/NCT02279004
NCT02332668,"A Phase I/II Study of Pembrolizumab (MK-3475) in Children With Advanced Melanoma or a PD-L1 Positive Advanced, Relapsed or Refractory Solid Tumor or Lymphoma (KEYNOTE-051)",Phase 1/Phase 2,Recruiting,Interventional,Melanoma; Lymphoma; Solid Tumor; Classical Hodgkin Lymphoma; Microsatellite-instability-high Solid Tumor,Pembrolizumab,,Merck Sharp & Dohme LLC,,370,2015-03-18,2027-10-25,Brazil; France; Germany; Israel; Italy; Netherlands; Portugal; South Korea; Sweden; United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT02332668
NCT02333604,Cancer Experience Registry: An Online Survey Research Study to Understand the Experiences of Cancer Patients and Caregivers,,Recruiting,Observational,Neoplasms; Cancer; Caregiver,,,"Cancer Support Community, Research and Training Institute, Philadelphia",,15000,2013-03-05,2035-12-05,United States,No,https://clinicaltrials.gov/study/NCT02333604
NCT02339571,Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients With Unresectable Stage III or Stage IV Melanoma,Phase 2/Phase 3,Recruiting,Interventional,Stage III Cutaneous Melanoma AJCC v7; Stage IV Cutaneous Melanoma AJCC v6 and v7,Biospecimen Collection; Computed Tomography; Echocardiography Test; Ipilimumab; Magnetic Resonance Elastography; Multigated Acquisition Scan; Nivolumab; Sargramostim,,National Cancer Institute (NCI),,600,2015-11-23,2033-06-30,United States,No,https://clinicaltrials.gov/study/NCT02339571
NCT02402244,"The Project: EveryChild Protocol: A Registry, Eligibility Screening, Biology and Outcome Study",,Recruiting,Observational,Adrenal Gland Pheochromocytoma; Carcinoma In Situ; Central Nervous System Neoplasm; Childhood Immature Teratoma; Childhood Kidney Neoplasm; Childhood Langerhans Cell Histiocytosis; Childhood Mature Teratoma; Congenital Mesoblastic Nephroma; Desmoid Fibromatosis; Ganglioneuroma; Lymphoproliferative Disorder; Malignant Neoplasm; Malignant Solid Neoplasm; Melanocytic Neoplasm; Myeloproliferative Neoplasm; Neoplasm of Uncertain Malignant Potential; Neuroendocrine Neoplasm; Stromal Neoplasm,Cytology Specimen Collection Procedure; Medical Chart Review,,Children's Oncology Group,National Cancer Institute (NCI),75000,2015-11-03,2030-12-31,Australia; Canada; New Zealand; Puerto Rico; Saudi Arabia; United States,No,https://clinicaltrials.gov/study/NCT02402244
NCT02670707,Randomization of Cytarabine Monotherapy Versus Standard-of-Care Vinblastine/Prednisone for Frontline Treatment of Langerhans Cell Histiocytosis (TXCH LCH0115),Phase 3,Recruiting,Interventional,Langerhans Cell Histiocytosis,Cytarabine; Vinblastine/prednisone,,Baylor College of Medicine,,124,2016-03-07,2029-01-05,United States,No,https://clinicaltrials.gov/study/NCT02670707
NCT02693535,Targeted Agent and Profiling Utilization Registry (TAPUR) Study,Phase 2,Recruiting,Interventional,"Lymphoma, Non-Hodgkin; Multiple Myeloma; Advanced Solid Tumors",Palbociclib; Sunitinib; Temsirolimus; Trastuzumab and Pertuzumab; Vemurafenib and Cobimetinib; Regorafenib; Olaparib; Pembrolizumab; Nivolumab and Ipilimumab; Abemaciclib; Talazoparib; Atezolizumab and PHESGO; Atezolizumab and Talazoparib; Entrectinib; Larotrectinib; Tucatinib plus Trastuzumab Subcutaneous (SC); Futibatinib,,American Society of Clinical Oncology,"AstraZeneca; Bayer; Bristol-Myers Squibb; Eli Lilly and Company; Genentech, Inc.; Merck Sharp & Dohme LLC; Pfizer; Boehringer Ingelheim; Seagen Inc.; Taiho Oncology, Inc.",4200,2016-03-14,2028-12-31,United States,No,https://clinicaltrials.gov/study/NCT02693535
NCT02775461,Pancreas Disease and High Risk Registry,,Recruiting,Observational,Pancreas Cancer; Pancreatitis; Chronic Pancreatitis; Pancreatic Cyst; Family History of Pancreas Cancer; Genetic Mutations,,,Icahn School of Medicine at Mount Sinai,,1116,2013-03-01,2033-11-05,United States,No,https://clinicaltrials.gov/study/NCT02775461
NCT03042221,Early Rebiopsy to Identify Mechanisms and Biomarkers of Tumor Cell Survival Following Systemic Therapy for Lung Cancer,,Recruiting,Observational,"Non-Small Cell Carcinoma of Lung, TNM Stage 4; Non-Small Cell Lung Cancer; EGFR Gene Mutation; ALK Gene Mutation; ROSE Cluster 1; BRAF V600E",,,"University of Colorado, Denver",,100,2016-05-10,2027-09-30,United States,No,https://clinicaltrials.gov/study/NCT03042221
NCT03050268,Familial Investigations of Childhood Cancer Predisposition,,Recruiting,Observational,Acute Leukemia; Adenomatous Polyposis; Adrenocortical Carcinoma; AML; BAP1 Tumor Predisposition Syndrome; Carney Complex; Choroid Plexus Carcinoma; Constitutional Mismatch Repair Deficiency Syndrome; Diamond-Blackfan Anemia; DICER1 Syndrome; Dyskeratosis Congenita; Emberger Syndrome; Familial Acute Myeloid Leukemia; Familial Adenomatous Polyposis; Fanconi Anemia; Familial Cancer; Familial Wilms Tumor; Familial Neuroblastoma; GIST; Hereditary Breast and Ovarian Cancer; Hereditary Paraganglioma-Pheochromocytoma Syndrome; Hodgkin Lymphoma; Juvenile Polyposis; Li-Fraumeni Syndrome; Lynch Syndrome; MDS; Melanoma Syndrome; Multiple Endocrine Neoplasia Type 1; Multiple Endocrine Neoplasia Type 2; Neuroblastoma; Neurofibromatosis Type 1; Neurofibromatosis Type II; Nevoid Basal Cell Carcinoma Syndrome; Non Hodgkin Lymphoma; Noonan Syndrome and Other Rasopathy; Overgrowth Syndromes; Pancreatic Cancer; Peutz-Jeghers Syndrome; Pheochromocytoma/Paraganglioma; PTEN Hamartoma Tumor Syndrome; Retinoblastoma; Rhabdoid Tumor Predisposition Syndrome; Rhabdomyosarcoma; Rothmund-Thomson Syndrome; Tuberous Sclerosis; Von Hippel-Lindau Disease,,,St. Jude Children's Research Hospital,,3000,2017-04-06,2037-03-31,United States,No,https://clinicaltrials.gov/study/NCT03050268
NCT03138161,"SAINT: A Phase 1/2 Study of Safe Amounts of IPLIMUMAB, NIVOLUMAB and TRABECTEDIN for Previously Treated Advanced Soft Tissue Sarcoma (STS)",Phase 1/Phase 2,Recruiting,Interventional,Advanced Soft Tissue Sarcoma; Metastatic Soft Tissue Sarcoma,Trabectedin; Ipilimumab; Nivolumab,,"Sarcoma Oncology Research Center, LLC",,250,2017-04-13,2031-07-31,United States,No,https://clinicaltrials.gov/study/NCT03138161
NCT03723928,Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored With Serum Tumor Marker Directed Disease Monitoring (STMDDM) Versus Usual Care in Patients With Metastatic Hormone Receptor Positive Breast Cancer,Not Applicable,Recruiting,Interventional,Anatomic Stage IV Breast Cancer AJCC v8; Estrogen Receptor Positive; HER2/Neu Negative; Progesterone Receptor Positive; Prognostic Stage IV Breast Cancer AJCC v8; Elevated CA15-3 or CEA or CA27-29,Usual care disease monitoring; Serum Tumor Marker directed disease monitoring; Quality-of-Life Assessment; Anxiety Questionnaire Administration,,SWOG Cancer Research Network,National Cancer Institute (NCI),739,2018-09-17,2036-12-01,Guam; Puerto Rico; United States,No,https://clinicaltrials.gov/study/NCT03723928
NCT03743298,Phase 1B Trial of AV-MEL-1 (Autologous Dendritic Cells Loaded With Autologous Tumor Antigens) With Anti-PD-1 Checkpoint Inhibitors in Metastatic Melanoma,Phase 1,Recruiting,Interventional,Metastatic Melanoma,AV-MEL-1,,"Aivita Biomedical, Inc.",,20,2021-04-21,2026-05-05,United States,No,https://clinicaltrials.gov/study/NCT03743298
NCT03803553,Early Identification and Treatment of Occult Metastatic Disease in Stage III Colon Cancer,Phase 3,Recruiting,Interventional,Metastatic Colon Cancer; Stage III Colon Cancer,FOLFIRI Protocol; ACTIVE SURVEILLANCE; Nivolumab Protocol; Encorafenib/Binimetinib/Cetuximab Protocol; Trastuzumab + Pertuzumab,,Massachusetts General Hospital,Stand Up To Cancer,400,2020-04-16,2027-12-05,United States,No,https://clinicaltrials.gov/study/NCT03803553
NCT03899155,Pan-Tumor Study for Long-term Treatment of Cancer Patients Who Have Participated in BMS Sponsored Trials Investigating Nivolumab and Other Cancer Therapies,Phase 2,Recruiting,Interventional,Cancer,Nivolumab; Ipilimumab; Cabozantinib; Trametinib; Relatlimab; Nivolumab + Relatlimab; Capecitabine; Bevacizumab; Temozolomide; Rucaparib; Daratumumab; Regorafinib; Leucovorin; Fluorouracil; Oxaliplatin; Enzalutamide; Sunitinib; Pemetrexed; Pembrolizumab,,Bristol-Myers Squibb,"Exelixis; Novartis; Clovis Oncology, Inc.; Janssen Pharmaceuticals",1500,2019-08-09,2029-08-25,Argentina; Australia; Austria; Belgium; Brazil; Canada; Chile; China; Czechia; Denmark; Finland; France; Germany; Greece; Hong Kong; Hungary; Ireland; Israel; Italy; Japan; Mexico; Netherlands; New Zealand; Norway; Peru; Poland; Portugal; Puerto Rico; Romania; Russia; South Korea; Spain; Sweden; Switzerland; Taiwan; Turkey (Türkiye); United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT03899155
NCT03997786,"A Multicenter, Randomized, Placebo and Active Comparator-controlled Clinical Trial to Study the Efficacy, Safety and Pharmacokinetics (PK) of Tildrakizumab in Pediatric Subjects From 6 to <18 Years of Age With Moderate to Severe Chronic Plaque Psoriasis",Phase 2/Phase 3,Recruiting,Interventional,Moderate-to-severe Chronic Plaque Psoriasis,Tildrakizumab; Placebo; Tildrakizumab; Tildrakizumab; Tildrakizumab; Etanercept; Placebo,,Sun Pharmaceutical Industries Limited,,130,2020-01-15,2031-12-05,Hungary; India; Poland; Slovakia; Spain; United States,No,https://clinicaltrials.gov/study/NCT03997786
NCT04079179,"A Phase 2 Study to Assess the Safety and Efficacy of Cobimetinib in Refractory Langerhans Cell Histiocytosis, LCH-Associated Neurodegenerative Disease, and Other Histiocytic Disorders.",Phase 2,Recruiting,Interventional,"Langerhan's Cell Histiocytosis; Juvenile Xanthogranuloma; Erdheim-Chester Disease; Rosai Dorfman Disease; Neuro-Degenerative Disease; Histiocytic Sarcoma; Histiocytic Disorders, Malignant",Cobimetinib,,Carl Allen,"Baylor College of Medicine; North American Consortium for Histiocytosis; Genentech, Inc.",90,2021-04-19,2029-12-05,United States,No,https://clinicaltrials.gov/study/NCT04079179
NCT04119024,Phase I Dose Escalation Study of Systemically Administered IL13Ra2 Chimeric Antigen Receptor (CAR) T Cells After a Nonmyeloablative Conditioning Regimen in Patients With Metastatic Melanoma and Other Solid Tumors,Phase 1,Recruiting,Interventional,Metastatic Malignant Solid Neoplasm; Metastatic Melanoma; Pathologic Stage IIIC Cutaneous Melanoma AJCC v8; Pathologic Stage IV Cutaneous Melanoma AJCC v8; Recurrent Malignant Solid Neoplasm; Refractory Malignant Solid Neoplasm; Uveal Melanoma; Acral Melanoma; Neuroendocrine Tumors; Paraganglioma; Pheochromocytoma; Adrenocortical Carcinoma; Pancreatic Neuroendocrine Tumor; Thyroid Cancer; Breast Cancer; Lung Adenocarcinoma; Head and Neck Squamous Cell Carcinoma,Biopsy; Biospecimen Collection; Computed Tomography; Cyclophosphamide; Fludarabine Phosphate; Fludeoxyglucose F-18; IL13Ralpha2-specific Hinge-optimized 4-1BB-co-stimulatory CAR/Truncated CD19-expressing Autologous TN/MEM Cells; Magnetic Resonance Imaging; Positron Emission Tomography,,Anusha Kalbasi,Parker Institute for Cancer Immunotherapy; Melanoma Research Alliance; California Institute for Regenerative Medicine (CIRM); City of Hope National Medical Center; Jonsson Comprehensive Cancer Center,18,2025-10-07,2026-10-05,United States,No,https://clinicaltrials.gov/study/NCT04119024
NCT04130516,"A Multicenter Phase 1-2A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of LNS8801 in Patients With Advanced Cancer With and Without Pembrolizumab",Phase 1/Phase 2,Recruiting,Interventional,"Solid Tumor, Adult","LNS8801 -Small molecule, orally bioavailable, selective agonist of GPER; Pembrolizumab - anti-PD-1 antibody",,"Linnaeus Therapeutics, Inc.",Merck Sharp & Dohme LLC,200,2019-10-21,2027-12-15,United States,No,https://clinicaltrials.gov/study/NCT04130516
NCT04166409,A Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine Versus Selumetinib (NSC# 748727) in Newly Diagnosed or Previously Untreated Low-Grade Glioma (LGG) Not Associated With BRAFV600E Mutations or Systemic Neurofibromatosis Type 1 (NF1),Phase 3,Recruiting,Interventional,Low Grade Astrocytoma; Low Grade Glioma; Metastatic Low Grade Astrocytoma; Metastatic Low Grade Glioma; WHO Grade 1 Glioma; WHO Grade 2 Glioma,Biospecimen Collection; Carboplatin; Echocardiography Test; Magnetic Resonance Imaging; Questionnaire Administration; Selumetinib Sulfate; Vincristine Sulfate,,National Cancer Institute (NCI),,170,2020-01-31,2030-12-31,Canada; Puerto Rico; United States,No,https://clinicaltrials.gov/study/NCT04166409
NCT04262466,Phase 1/2 Study of IMC-F106C in Advance PRAME-Positive Cancers,Phase 1/Phase 2,Recruiting,Interventional,Select Advanced Solid Tumors,Brenetafusp; Brenetafusp and pembrolizumab; Brenetafusp and chemotherapy; Brenetafusp and monoclonal antibodies and chemotherapy; Brenetafusp and tebentafusp; Brenetafusp and bevacizumab; Brenetafusp and kinase inhibitors,,Immunocore Ltd,,727,2020-02-25,2026-08-05,Australia; Austria; Belgium; Brazil; Canada; France; Germany; Ireland; Italy; Netherlands; New Zealand; Poland; South Korea; Spain; Switzerland; United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT04262466
NCT04291105,Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Patients With Select Solid Tumors,Phase 2,Recruiting,Interventional,Melanoma; Head and Neck Squamous Cell Carcinoma; Colo-rectal Cancer,VV1; Cemiplimab,,"Vyriad, Inc.",Regeneron Pharmaceuticals,87,2020-04-24,2025-12-05,Brazil; United States,No,https://clinicaltrials.gov/study/NCT04291105
NCT04370587,"A Phase 1/2a, Open-Label, Dose Escalation and Expansion Study of the Safety and Tolerability of T3011 Administered Via Intratumoral Injection as a Single Agent and in Combination With Intravenous Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors",Phase 1/Phase 2,Recruiting,Interventional,Solid Tumor; Melanoma; HNSCC; Sarcoma; Squamous Cell Carcinoma; NSCLC,T3011; T3011 + pembrolizumab,,ImmVira Pharma Co. Ltd,,30,2020-09-17,2027-01-10,Australia; United States,No,https://clinicaltrials.gov/study/NCT04370587
NCT04541108,A Phase 0 Master Protocol Using the CIVO® Platform to Evaluate Intratumoral Microdoses of Anti-Cancer Therapies in Patients With Solid Tumors,Early Phase 1,Recruiting,Interventional,Solid Tumor,Rilvegostomig; Volrustomig; Sabestomig; Pembrolizumab,,Presage Biosciences,,15,2021-07-26,2031-12-05,United States,No,https://clinicaltrials.gov/study/NCT04541108
NCT04572451,Phase I Study Investigating the Safety of Stereotactic Body Radiotherapy (SBRT) With Anti-PD1 and Anti-IL-8 for the Treatment of Multiple Metastases in Advanced Solid Tumors and Melanoma,Phase 1,Recruiting,Interventional,"Melanoma; Unresectable Solid Tumors; Neoplasms; Neoplasms by Histologic Type; Neoplasms by Site; Antineoplastic Agents, Immunological; Antineoplastic Agents; Immune Checkpoint Inhibitors; Molecular Mechanisms of Pharmacological Action; Nivolumab",nivolumab; BMS-986253; Stereotactic Body Radiotherapy (SBRT),,Yana Najjar,Bristol-Myers Squibb,50,2021-11-29,2027-05-31,United States,No,https://clinicaltrials.gov/study/NCT04572451
NCT04598009,A Phase II Study of Binimetinib in Combination With Imatinib in Patients With Advanced KIT-Mutant Melanoma,Phase 2,Recruiting,Interventional,Melanoma Stage III; Melanoma Stage IV,Binimetinib; Imatinib,,"University of California, San Francisco",Array BioPharma,25,2021-03-03,2027-05-31,United States,No,https://clinicaltrials.gov/study/NCT04598009
NCT04693377,Cryoablation Combined With Stereotactic Body Radiation Therapy for the Treatment of Painful Bone Metastases,Not Applicable,Recruiting,Interventional,Castration-Resistant Prostate Carcinoma; Metastatic Colorectal Carcinoma; Metastatic Malignant Neoplasm in the Bone; Metastatic Malignant Solid Neoplasm; Metastatic Melanoma; Metastatic Prostate Carcinoma; Metastatic Renal Cell Carcinoma; Metastatic Sarcoma; Metastatic Thyroid Gland Carcinoma; Metastatic Urothelial Carcinoma; Stage IV Colorectal Cancer AJCC v8; Stage IV Prostate Cancer AJCC v8; Stage IV Renal Cell Cancer AJCC v8; Stage IVA Colorectal Cancer AJCC v8; Stage IVA Prostate Cancer AJCC v8; Stage IVB Colorectal Cancer AJCC v8; Stage IVB Prostate Cancer AJCC v8; Stage IVC Colorectal Cancer AJCC v8,Cryosurgery; Quality-of-Life Assessment; Stereotactic Body Radiation Therapy,,M.D. Anderson Cancer Center,,40,2021-03-16,2027-04-01,United States,No,https://clinicaltrials.gov/study/NCT04693377
NCT04697576,Intralesional Influenza Vaccine for Patients With Melanoma,Phase 1,Recruiting,Interventional,Clinical Stage I Cutaneous Melanoma AJCC v8; Clinical Stage IA Cutaneous Melanoma AJCC v8; Clinical Stage IB Cutaneous Melanoma AJCC v8; Clinical Stage II Cutaneous Melanoma AJCC v8; Clinical Stage IIA Cutaneous Melanoma AJCC v8; Clinical Stage IIB Cutaneous Melanoma AJCC v8; Clinical Stage IIC Cutaneous Melanoma AJCC v8; Clinical Stage IV Cutaneous Melanoma AJCC v8; Metastatic Melanoma,Ipilimumab; Nivolumab; Pembrolizumab; Quadrivalent Inactivated Influenza Vaccine; Resection; Nivolumab + Relatlimab,,Carlo Contreras,,36,2021-10-20,2026-12-31,United States,No,https://clinicaltrials.gov/study/NCT04697576
NCT04712877,LEADER Neoadjuvant Screening Trial: LCMC4 Evaluation of Actionable Drivers in Early Stage Lung Cancers,,Recruiting,Observational,NSCLC,"ctDNA, tumor NGS",,Lung Cancer Mutation Consortium,Lung Cancer Research Foundation,1000,2022-06-15,2026-06-15,United States,No,https://clinicaltrials.gov/study/NCT04712877
NCT04741997,A Randomized Pilot Trial of Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib and Binimetinib in Advanced Melanoma,Early Phase 1,Recruiting,Interventional,Melanoma Stage III; Melanoma Stage IV; BRAF V600 Mutation,Encorafenib Pill; Binimetinib Pill; Nivolumab,,H. Lee Moffitt Cancer Center and Research Institute,Pfizer,50,2021-05-24,2026-07-05,United States,No,https://clinicaltrials.gov/study/NCT04741997
NCT04752826,"Phase 1/2a Open-Label, Dose-Escalation, Multicenter, FIH, Consecutive-Cohort, Clinical Trial of BI-1808, a Monoclonal Antibody to TNFR 2 As a Single Agent and in Combination with Pembrolizumab (MK-3475-D20) in Subjects with Advanced Malignancies",Phase 1/Phase 2,Recruiting,Interventional,Advanced Malignancies; Ovarian Cancer; T-cell Lymphoma; Melanoma,BI-1808; Pembrolizumab (KEYTRUDA® ) 25 Mg/mL Solution for Injection,,BioInvent International AB,Merck Sharp & Dohme LLC,176,2021-01-25,2028-01-15,Denmark; Hungary; Russia; Sweden; United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT04752826
NCT04852887,"A Phase III Clinical Trial Evaluating De-Escalation of Breast Radiation for Conservative Treatment of Stage I, Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer",Phase 3,Recruiting,Interventional,Stage I Breast Cancer,"Radiation and Endocrine Therapy (Tamoxifen, Anastrozol, Letrozole, Exemestane); Endocrine Therapy (Tamoxifen, Anastrozol, Letrozole, Exemestane)",,NRG Oncology,National Cancer Institute (NCI),1670,2021-06-07,2041-07-05,Canada; Hong Kong; Japan; United States,No,https://clinicaltrials.gov/study/NCT04852887
NCT04930783,A Phase Ib Study of NeoVax in Combination With CDX-301 and Nivolumab or Pembrolizumab and in Patients With Melanoma,Phase 1,Recruiting,Interventional,Melanoma; Metastatic Melanoma,CDX-301; NEOVAX; Nivolumab; Pembrolizumab,,Dana-Farber Cancer Institute,Celldex Therapeutics,30,2022-01-03,2030-09-30,United States,No,https://clinicaltrials.gov/study/NCT04930783
NCT05009992,"A Combination Therapy Trial Using an Adaptive Platform Design for Children and Young Adults With Diffuse Midline Gliomas (DMGs) Including Diffuse Intrinsic Pontine Gliomas (DIPGs) at Initial Diagnosis, Post-Radiation Therapy and at Time of Progression",Phase 2,Recruiting,Interventional,"Diffuse Intrinsic Pontine Glioma; Diffuse Midline Glioma, H3 K27M-Mutant; Recurrent Diffuse Intrinsic Pontine Glioma; Recurrent Diffuse Midline Glioma, H3 K27M-Mutant; Recurrent WHO Grade III Glioma; WHO Grade III Glioma",ONC201; Radiation Therapy; Paxalisib; DNX-2401,,"University of California, San Francisco",The Chad-Tough Defeat DIPG Foundation; Mithil Prasad Foundation; Storm the Heavens Fund; National Institute of Neurological Disorders and Stroke (NINDS); Jazz Pharmaceuticals; Neeve Kolte and Brave Ronil Foundation; Will Meeker Foundation; CV Biomanufacturing,360,2021-10-20,2029-06-30,Australia; Israel; Netherlands; New Zealand; Switzerland; United States,No,https://clinicaltrials.gov/study/NCT05009992
NCT05040360,Randomized Phase II Trial of Postoperative Adjuvant Capecitabine and Temozolomide Versus Observation in High-Risk Pancreatic Neuroendocrine Tumors,Phase 2,Recruiting,Interventional,Metastatic Malignant Neoplasm in the Liver; Pancreatic Neuroendocrine Tumor; Stage I Pancreatic Neuroendocrine Tumor AJCC v8; Stage II Pancreatic Neuroendocrine Tumor AJCC v8; Stage III Pancreatic Neuroendocrine Tumor AJCC v8,Capecitabine; Temozolomide,,SWOG Cancer Research Network,National Cancer Institute (NCI),141,2022-05-05,2027-03-31,Mexico; United States; Uruguay,No,https://clinicaltrials.gov/study/NCT05040360
NCT05053555,High Dose-Rate Brachytherapy for the Treatment of Both Primary and Secondary Unresectable Liver Malignancies,Not Applicable,Recruiting,Interventional,Liver Malignant Tumors; Cholangiocarcinoma Metastatic; Pancreatic Cancer; Melanoma,high dose rate brachytherapy; high dose rate brachytherapy,,M.D. Anderson Cancer Center,,60,2022-04-24,2027-01-31,United States,No,https://clinicaltrials.gov/study/NCT05053555
NCT05059444,ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation,,Recruiting,Observational,Bladder Carcinoma; Ureter Carcinoma; Renal Pelvis Carcinoma; Non-small Cell Lung Cancer; Invasive Breast Carcinoma; Cutaneous Melanoma; Esophageal Carcinoma; Gastroesophageal Junction Carcinoma; Gastric Adenocarcinoma; Pancreatic Adenocarcinoma; Squamous Cell Carcinoma of the Head and Neck; Epithelial Ovarian Carcinoma; Fallopian Tube Carcinoma; Endometrial Carcinoma; Renal Cell Carcinoma; Rectal Adenocarcinoma,Guardant Reveal,,"Guardant Health, Inc.",,2020,2021-09-07,2029-08-05,France; Germany; Italy; Spain; United States,No,https://clinicaltrials.gov/study/NCT05059444
NCT05076760,Phase I Study Evaluating MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors,Phase 1,Recruiting,Interventional,Solid Tumor; Advanced Cancer; Metastatic Cancer; Non Small Cell Lung Cancer; Cutaneous Squamous Cell Carcinoma; Merkel Cell Carcinoma; Melanoma; Pancreatic Cancer; Triple Negative Breast Cancer; Head and Neck Cancer,MEM-288 Intratumoral Injection; Nivolumab; Docetaxel,,"Memgen, Inc.",H. Lee Moffitt Cancer Center and Research Institute; Duke Cancer Institute,40,2022-04-21,2031-12-05,United States,No,https://clinicaltrials.gov/study/NCT05076760
NCT05136196,Biomarker Stratified CaboZantinib (NSC#761968) and NivOlumab (NSC#748726) (BiCaZO) - A Phase II Study of Combining Cabozantinib and Nivolumab in Participants With Advanced Solid Tumors (IO Refractory Melanoma or HNSCC) Stratified by Tumor Biomarkers - an immunoMATCH Pilot Study,Phase 2,Recruiting,Interventional,Clinical Stage III Cutaneous Melanoma AJCC v8; Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8; Clinical Stage IV Cutaneous Melanoma AJCC v8; Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8; Locally Recurrent Head and Neck Squamous Cell Carcinoma; Locally Recurrent Hypopharyngeal Squamous Cell Carcinoma; Locally Recurrent Laryngeal Squamous Cell Carcinoma; Locally Recurrent Oral Cavity Squamous Cell Carcinoma; Locally Recurrent Oropharyngeal Squamous Cell Carcinoma; Metastatic Head and Neck Squamous Cell Carcinoma; Metastatic Hypopharyngeal Squamous Cell Carcinoma; Metastatic Laryngeal Squamous Cell Carcinoma; Metastatic Melanoma; Metastatic Oral Cavity Squamous Cell Carcinoma; Metastatic Oropharyngeal Squamous Cell Carcinoma; Recurrent Melanoma; Stage III Hypopharyngeal Carcinoma AJCC v8; Stage III Laryngeal Cancer AJCC v8; Stage III Lip and Oral Cavity Cancer AJCC v8; Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8; Stage IV Hypopharyngeal Carcinoma AJCC v8; Stage IV Laryngeal Cancer AJCC v8; Stage IV Lip and Oral Cavity Cancer AJCC v8; Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8; Unresectable Melanoma,Biopsy Procedure; Biospecimen Collection; Cabozantinib S-malate; Computed Tomography; Magnetic Resonance Imaging; Nivolumab,,National Cancer Institute (NCI),,150,2022-12-06,2027-01-01,United States,No,https://clinicaltrials.gov/study/NCT05136196
NCT05225428,Video Education With Result Dependent dIsclosure,Not Applicable,Recruiting,Interventional,Genetic Testing; Breast Cancer; Ovarian Cancer; Pancreatic Cancer; Prostate Cancer; Colorectal Cancer; Renal Cancer; Melanoma; Sarcoma,Video Education; Genetic Counseling,,Dana-Farber Cancer Institute,National Cancer Institute (NCI); National Human Genome Research Institute (NHGRI),1020,2022-08-04,2026-09-01,United States,No,https://clinicaltrials.gov/study/NCT05225428
NCT05379985,A Multicenter Open-Label Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS,Phase 1/Phase 2,Recruiting,Interventional,Non-small Cell Lung Cancer (NSCLC); Colorectal Cancer (CRC); Pancreatic Ductal Adenocarcinoma (PDAC); Advanced Solid Tumors,RMC-6236,,"Revolution Medicines, Inc.",,754,2022-05-31,2027-07-26,United States,No,https://clinicaltrials.gov/study/NCT05379985
NCT05463796,"InAdvance: Surveillance, Prevention, and Interception in a Population at Risk For Cancer",,Recruiting,Observational,"Cancer Risk; Cancer Predisposition Syndrome; Hereditary Cancer Prediction; Childhood Cancer Survivors; Adult Cancer Survivors; IARC Carcinogens; Smoking History; Lung Cancer; Ductal/Lobular Carcinoma; Barrett Esophagus; Pancreatic Precursor Lesions; Colonic Dysplasia/Adenomata; Non-Alcoholic Fatty Liver Disease; Non Alcoholic Steatohepatitis; Cirrhosis; High Grade Prostatic Epithelial Neoplasia; High-grade Bladder Urothelial Dysplasia/Carcinoma in Situ; Adenomatous Hyperplasia; High-risk Oral Precancerous Diseases; Melanocytic Lesion, Adult; Hematologic Malignancy; Lung; Node; Serous Tubal Intraepithelial Carcinoma; Endometrial Intraepithelial Neoplasia; Cervical and Endocervical Carcinoma in Situ; Vulvar Intraepithelial Neoplasia; Nephrogenic Rests; Benign Bone Lesions With Risk of Malignant Degeneration; Giant Cell Tumor; Osteochondroma; Spitz Nevus",Samples,,Dana-Farber Cancer Institute,,5000,2023-04-25,2032-03-25,United States,No,https://clinicaltrials.gov/study/NCT05463796
NCT05503797,"A Phase 2 Master Protocol to Assess the Efficacy and Safety of FORE8394, an Inhibitor of BRAF Class 1 and Class 2 Alterations, in Participants With Cancer Harboring BRAF Alterations",Phase 2,Recruiting,Interventional,Cancer Harboring BRAF Alterations; HGG; LGG; Solid Tumors,Plixorafenib,,Fore Biotherapeutics,,254,2023-02-21,2026-12-28,Australia; Canada; France; Germany; Italy; Norway; South Korea; Spain; Sweden; United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT05503797
NCT05520099,Observational Basket Trial to Collect Tissue to Develop and Train a Live Tumor Diagnostic Platform (ELEPHAS-02),,Recruiting,Observational,Immunotherapy; Cancer; Bladder Cancer; Urothelial Carcinoma Bladder; Kidney Cancer; Clear Cell Renal Cell Cancer (ccRCC); Colorectal Cancer; MSI-H Colorectal Cancer; DMMR Colorectal Cancer; Head and Neck Cancer (H&N); Squamous Cell Carcinoma Head and Neck Cancer (HNSCC); Liver Cancer; Hepatocellular Carcinoma (HCC); Lung Cancer (NSCLC); NSCLC (Non-small Cell Lung Cancer); Skin Cancer; Cutaneous Melanoma; Endometrial Cancer; Solid Tumor Cancer,"Core Needle Biopsy, Forceps Biopsy, Punch Biopsy",,Elephas,,416,2023-06-26,2027-01-05,United States,No,https://clinicaltrials.gov/study/NCT05520099
NCT05538130,A PHASE 1A/B OPEN-LABEL MASTER STUDY OF PF-07799544 AS A SINGLE-AGENT AND IN COMBINATION WITH OTHER TARGETED AGENTS IN PARTICIPANTS WITH ADVANCED SOLID TUMORS,Phase 1,Recruiting,Interventional,Melanoma; Glioma; Thyroid Cancer; Non-Small Cell Lung Cancer; Malignant Neoplasms; Brain Neoplasms; Colorectal Cancer,PF-07799544; PF-07799933; encorafenib,,Pfizer,,124,2022-11-30,2028-10-11,Australia; Brazil; Canada; Israel; United States,No,https://clinicaltrials.gov/study/NCT05538130
NCT05576896,"A Single-Arm, Phase II Study of Autophagy Modulation Using Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab in Metastatic BRAF-mutated Colorectal Cancer Refractory to Standard Therapies",Phase 2,Recruiting,Interventional,Stage IV Colorectal Cancer Positive for BRAF V600E Mutation; Colorectal Cancer; Colorectal Cancer Stage IV,Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab,,Northwestern University,National Cancer Institute (NCI),43,2022-10-10,2028-07-01,United States,No,https://clinicaltrials.gov/study/NCT05576896
NCT05584670,"A Phase 1/2, Open Label, First-in-human, Dose Escalation and Expansion Study for the Evaluation of Safety, Pharmacokinetics, Pharmacodynamics, and Anti-tumor Activity of SAR445877 Administered as Monotherapy or in Combination With Other Anticancer Therapies in Adults With Advanced Solid Tumors",Phase 1/Phase 2,Recruiting,Interventional,Solid Tumor,SAR445877; Cetuximab; ADG126; Bevacizumab; Nivolumab; Ipilimumab,,Sanofi,,542,2022-11-29,2028-06-28,Chile; Israel; Netherlands; Spain; United States,No,https://clinicaltrials.gov/study/NCT05584670
NCT05677490,Randomized Phase III Trial of mFOLFIRINOX vs. FOLFOX With Nivolumab for First-Line Treatment of Metastatic HER2- Gastroesophageal Adenocarcinoma,Phase 3,Recruiting,Interventional,Advanced Esophageal Adenocarcinoma; Advanced Gastric Adenocarcinoma; Advanced Gastroesophageal Junction Adenocarcinoma; Clinical Stage III Esophageal Adenocarcinoma AJCC v8; Clinical Stage III Gastric Cancer AJCC v8; Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8; Clinical Stage IV Esophageal Adenocarcinoma AJCC v8; Clinical Stage IV Gastric Cancer AJCC v8; Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8; Metastatic Esophageal Adenocarcinoma; Metastatic Gastric Adenocarcinoma; Metastatic Gastroesophageal Junction Adenocarcinoma; Unresectable Esophageal Adenocarcinoma; Unresectable Gastric Adenocarcinoma; Unresectable Gastroesophageal Junction Adenocarcinoma,Fluorouracil; Leucovorin Calcium; Oxaliplatin; Irinotecan; Nivolumab; Magnetic Resonance Imaging; Computed Tomography; Biospecimen Collection; Questionnaire Administration,,Alliance for Clinical Trials in Oncology,National Cancer Institute (NCI),382,2023-01-31,2028-11-08,Puerto Rico; United States,No,https://clinicaltrials.gov/study/NCT05677490
NCT05746897,"A Phase 1 Study to Investigate the Safety, Tolerability, Pharmacokinetics/Pharmacodynamics, and Antitumor Activity of NM1F as Monotherapy and in Combination With Pembrolizumab in Subjects With Locally Advanced/Metastatic Solid Tumors",Phase 1,Recruiting,Interventional,Ovarian Cancer; Melanoma; Triple Negative Breast Cancer; Colorectal Cancer,NM1F Injection; Pembrolizumab injection,,"Hefei TG ImmunoPharma Co., Ltd.",,38,2023-04-13,2027-09-30,United States,No,https://clinicaltrials.gov/study/NCT05746897
NCT05779423,A Phase II Study of Core Needle Biopsy and Cryoablation of an Enlarging Tumor in Patients With Advanced Melanoma Receiving Post-progression Dual Immune Checkpoint Inhibitor Therapy,Phase 2,Recruiting,Interventional,Metastatic Melanoma; Skin Cancer,Ipilimumab; Nivolumab; Cryoablation,,Massachusetts General Hospital,,37,2023-09-23,2028-01-01,United States,No,https://clinicaltrials.gov/study/NCT05779423
NCT05786924,"A Phase 1/2, Open-label Study of Oral S241656 (BDTX-4933) as Monotherapy and in Combination With Other Anti-Cancer Therapies in Patients With KRAS, BRAF and Other Selected RAS/MAPK Mutation-Positive Malignancies",Phase 1/Phase 2,Recruiting,Interventional,Non-small Cell Lung Cancer; Histiocytic Neoplasm; Histiocytosis; BRAF Gene Mutation; BRAF V600E; BRAF V600 Mutation; BRAF Mutation-Related Tumors; BRAF; Metastatic Lung Non-Small Cell Carcinoma; Metastatic Lung Cancer; Recurrent Lung Cancer; Recurrent Lung Non-Small Cell Carcinoma; NSCLC; Solid Tumor; Solid Carcinoma; KRAS G12D; KRAS G12V; KRAS Mutation-Related Tumors; NRAS Gene Mutation; Thyroid Cancer; Thyroid Carcinoma; Colorectal Cancer; Colorectal Carcinoma; Recurrent Histiocytic and Dendritic Cell Neoplasm; Brain Metastases; Recurrent NSCLC; KRAS G13C; Acquired Resistance to KRAS G12C Inhibitor; KRAS G12A; KRAS G12F; KRAS G12R; KRAS G13D,S241656; FOLFOX6/FOLFOX7; FOLFIRI; Cetuximab; Panitumumab; Gemcitabine; Nab-paclitaxel,,Institut de Recherches Internationales Servier,,554,2023-04-18,2028-06-05,United States,No,https://clinicaltrials.gov/study/NCT05786924
NCT05828069,Phase 2 Study of Tovorafenib (DAY101) in Relapsed and Refractory Langerhans Cell Histiocytosis,Phase 2,Recruiting,Interventional,Recurrent Langerhans Cell Histiocytosis; Refractory Langerhans Cell Histiocytosis,Biospecimen Collection; Bone Marrow Aspiration; Bone Marrow Biopsy; Computed Tomography; Echocardiography Test; FDG-Positron Emission Tomography and Computed Tomography Scan; Lumbar Puncture; Multigated Acquisition Scan; Tovorafenib,,National Cancer Institute (NCI),,48,2024-03-28,2028-09-30,Australia; Canada; United States,No,https://clinicaltrials.gov/study/NCT05828069
NCT05844982,A Trial Evaluating Intravitreal Faricimab (6.0 mg) Injections or Fluocinolone Acetonide (0.19 mg Intravitreal Implants vs Observation for Prevention of Visual Acuity Loss Due to Radiation Retinopathy,Phase 3,Recruiting,Interventional,Radiation Retinopathy; Visual Impairment,Faricimab; fluocinolone acetonide,,Jaeb Center for Health Research,"National Eye Institute (NEI); National Institutes of Health (NIH); Alimera Sciences; Genentech, Inc.",600,2023-11-21,2029-12-26,United States,No,https://clinicaltrials.gov/study/NCT05844982
NCT05859074,"A First-In-Human Phase I, Open Label, Safety and Tolerability Study of Escalating Multiple Doses of Intratumoral MQ710, a Multi-Transgene Expressing Modified Vaccinia Virus Ankara-Based Virotherapy, Alone and in Combination With the Systemic Checkpoint Inhibitor Pembrolizumab in Solid Tumors",Phase 1,Recruiting,Interventional,Cutaneous Squamous Cell Carcinoma; SCC - Squamous Cell Carcinoma; Basal Cell Carcinoma; BCC; BCC - Basal Cell Carcinoma; Melanoma; Merkel Cell Carcinoma; Sebaceous Carcinoma; Extramammary Paget Disease; Kaposi Sarcoma; Head and Neck Squamous Cell Carcinoma; HNSCC; Adnexal Carcinoma; Angiosarcoma; Cutaneous Neoplasm; Advanced Cancer; Metastatic Cancer; Refractory Cancer; Solid Tumor,MQ719; Pembrolizumab,,Memorial Sloan Kettering Cancer Center,,56,2023-05-04,2028-05-04,United States,No,https://clinicaltrials.gov/study/NCT05859074
NCT05868629,Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors,,Recruiting,Observational,Rare Unresectable or Metastatic BRAF V600E Mutation-positive Solid Tumors,Non-investigational,,Novartis Pharmaceuticals,,40,2024-02-06,2028-03-03,United States,No,https://clinicaltrials.gov/study/NCT05868629
NCT05907954,(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma,Phase 2,Recruiting,Interventional,Uveal Melanoma,Darovasertib,,IDEAYA Biosciences,,160,2023-07-03,2030-04-30,Australia; Canada; France; Germany; Italy; Netherlands; United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT05907954
NCT05929768,"Shorter Anthracycline-Free Chemo Immunotherapy Adapted to Pathological Response in Early Triple Negative Breast Cancer (SCARLET), A Randomized Phase III Study",Phase 3,Recruiting,Interventional,Anatomic Stage I Breast Cancer AJCC v8; Anatomic Stage II Breast Cancer AJCC v8; Anatomic Stage IIIA Breast Cancer AJCC v8; Anatomic Stage IIIB Breast Cancer AJCC v8; Early Stage Triple-Negative Breast Carcinoma,Biospecimen Collection; Carboplatin; Cyclophosphamide; Docetaxel; Doxorubicin; Paclitaxel; Pembrolizumab; Quality-of-Life Assessment; Questionnaire Administration; Surgical Procedure,,SWOG Cancer Research Network,National Cancer Institute (NCI),2400,2023-09-15,2033-04-05,Mexico; Puerto Rico; United States,No,https://clinicaltrials.gov/study/NCT05929768
NCT06011785,Using Silica 12CH to Mitigate the Effects and Symptoms of Silicosis in Brazil,Early Phase 1,Not yet recruiting,Interventional,Silicosis,Silica 12CH,,HOHM Foundation,,100,2024-03-01,2026-03-01,United States,No,https://clinicaltrials.gov/study/NCT06011785
NCT06074588,"A Randomized, Open-label, Phase 3 Study of MK-2870 vs Chemotherapy (Docetaxel or Pemetrexed) in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations",Phase 3,Recruiting,Interventional,Non-small Cell Lung Cancer (NSCLC),Sacituzumab tirumotecan; Docetaxel; Pemetrexed,,Merck Sharp & Dohme LLC,,556,2023-11-12,2030-03-11,Australia; Brazil; Canada; Chile; China; Czechia; France; Germany; Greece; Hong Kong; Israel; Italy; Japan; Malaysia; Mexico; Philippines; Poland; South Korea; Spain; Taiwan; Thailand; Turkey (Türkiye); United Kingdom; United States; Vietnam,No,https://clinicaltrials.gov/study/NCT06074588
NCT06090266,A Phase 1/2 Study of OR502 Alone and in Combination With Other Anti-cancer Agents in Subjects With Advanced Malignancies,Phase 1/Phase 2,Recruiting,Interventional,"Cancer; Tumor, Solid; Malignant Neoplasm; Metastatic Cancer; Advanced Solid Tumor; Cutaneous Melanoma; Non-small Cell Lung Cancer",OR502; Cemiplimab,,"OncoResponse, Inc.",,168,2023-10-24,2027-02-01,United States,No,https://clinicaltrials.gov/study/NCT06090266
NCT06102902,A Phase 1 Study of ZEN003694 (ZEN-3694) in Combination With Cetuximab and Encorafenib in Patients With Refractory BRAF V600E Metastatic Colorectal Cancer,Phase 1,Recruiting,Interventional,Metastatic Colorectal Adenocarcinoma; Recurrent Colorectal Adenocarcinoma; Refractory Colorectal Adenocarcinoma; Stage IV Colorectal Cancer AJCC v8,BET Bromodomain Inhibitor ZEN-3694; Biopsy Procedure; Biospecimen Collection; Cetuximab; Computed Tomography; Echocardiography Test; Encorafenib; Magnetic Resonance Imaging; Multigated Acquisition Scan,,National Cancer Institute (NCI),,30,2024-06-05,2027-01-30,United States,No,https://clinicaltrials.gov/study/NCT06102902
NCT06108479,"A Phase I/Ib, First-In-Human, Multi-Part, Open-Label Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of DF6215 Monotherapy and in Combination Therapy in Patients with Advanced (Unresectable, Recurrent, or Metastatic) Solid Tumors",Phase 1,Recruiting,Interventional,"Solid Tumor, Adult; Solid Tumor Cancer",DF6215; pembrolizumab; KEYTRUDA®,,Dragonfly Therapeutics,Merck Sharp & Dohme LLC,255,2023-11-28,2027-12-05,Australia; France; United States,No,https://clinicaltrials.gov/study/NCT06108479
NCT06190951,A Phase 2 Peri-operative Trial of Fianlimab and Cemiplimab Compared With Anti-PD1 Alone in Patients With Resectable Stage III and IV Melanoma,Phase 2,Recruiting,Interventional,Melanoma,cemiplimab; Fixed Dose Combination (FDC) cemiplimab+fianlimab; Placebo,,Regeneron Pharmaceuticals,,150,2024-09-18,2031-04-23,Australia; Canada; France; Germany; Italy; Spain; United States,No,https://clinicaltrials.gov/study/NCT06190951
NCT06194929,"Phase 1b/2 Trial of Defactinib and Avutometinib, With or Without Encorafenib, for the Treatment of Patients With Brain Metastases From Cutaneous Melanoma",Phase 1/Phase 2,Recruiting,Interventional,Cutaneous Melanoma; Brain Metastases,Defactinib; Avutometinib; Encorafenib,,University of Utah,"Verastem, Inc.",33,2024-03-20,2030-01-15,United States,No,https://clinicaltrials.gov/study/NCT06194929
NCT06216938,Phase I Pilot Study of RP1 in Primary Melanoma to Reduce the Risk of Sentinel Lymph Node Metastasis,Early Phase 1,Recruiting,Interventional,Melanoma,Vusolimogene oderparepvec (RP1),,Yana Najjar,Replimune Inc.,25,2024-03-07,2027-03-31,United States,No,https://clinicaltrials.gov/study/NCT06216938
NCT06249048,"A Phase 1/2, Open-label, Multi-center, First-in-human Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of STX-001 Delivered by Intratumoral Injection in Patients With Advanced Solid Tumors as a Monotherapy or in Combination With Pembrolizumab",Phase 1/Phase 2,Recruiting,Interventional,Advanced Solid Tumor,STX-001; Keytruda®,,Strand Therapeutics Inc.,,108,2024-05-03,2028-11-05,Australia; United States,No,https://clinicaltrials.gov/study/NCT06249048
NCT06265285,"Pilot Single-Arm, Pragmatic Trial of In-Home Versus In-Clinic Subcutaneous Nivolumab Administration Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program",Phase 2,Recruiting,Interventional,Advanced Esophageal Squamous Cell Carcinoma; Advanced Renal Cell Carcinoma; Clinical Stage II Esophageal Squamous Cell Carcinoma AJCC v8; Clinical Stage IIB Cutaneous Melanoma AJCC v8; Clinical Stage IIC Cutaneous Melanoma AJCC v8; Clinical Stage III Cutaneous Melanoma AJCC v8; Clinical Stage III Esophageal Squamous Cell Carcinoma AJCC v8; Clinical Stage IV Cutaneous Melanoma AJCC v8; Clinical Stage IV Esophageal Squamous Cell Carcinoma AJCC v8; Esophageal Carcinoma; Gastroesophageal Junction Adenocarcinoma; Hepatocellular Carcinoma; Locally Advanced Urothelial Carcinoma; Lung Non-Small Cell Carcinoma; Malignant Solid Neoplasm; Metastatic Colorectal Carcinoma; Metastatic Cutaneous Melanoma; Metastatic Esophageal Squamous Cell Carcinoma; Metastatic Head and Neck Squamous Cell Carcinoma; Metastatic Urothelial Carcinoma; Recurrent Esophageal Squamous Cell Carcinoma; Recurrent Head and Neck Squamous Cell Carcinoma; Renal Cell Carcinoma; Stage III Renal Cell Cancer AJCC v8; Stage IV Colorectal Cancer AJCC v8; Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8; Stage IV Renal Cell Cancer AJCC v8; Unresectable Cutaneous Melanoma; Unresectable Esophageal Squamous Cell Carcinoma; Urothelial Carcinoma; Unresectable Urothelial Carcinoma,Home Health Encounter; Nivolumab; Patient Monitoring; Questionnaire Administration,,Mayo Clinic,,50,2024-04-30,2026-12-31,United States,No,https://clinicaltrials.gov/study/NCT06265285
NCT06326411,"A Phase I, Open Label Single-arm Two-part Study to Investigate Safety, Pharmacokinetics, and Preliminary Efficacy of Pan-RAF/MEK Glue NST-628 Oral Tablets in Subject With Solid Tumors Harboring Genetic Alterations in the MAPK Pathway and With Other Solid Tumors",Phase 1,Recruiting,Interventional,"Oncology; MEK Mutation; RAF Gene Mutation; Ras (KRAS or NRAS) Gene Mutation; Melanoma; NSCLC; Glioma; Solid Tumor, Adult; MAPK Pathway Gene Mutation",NST-628,,"Nested Therapeutics, Inc",,230,2024-04-09,2029-11-05,Australia; United States,No,https://clinicaltrials.gov/study/NCT06326411
NCT06331377,Clinical and Molecular Characteristics of Histiocytic Disorders,,Recruiting,Observational,Histiocytic Disorder,Non-Interventional Study,,Mayo Clinic,,500,2017-07-27,2027-07-31,United States,No,https://clinicaltrials.gov/study/NCT06331377
NCT06402201,"Phase 1, First-in-Human Study to Assess the Safety, Tolerability and Anti-tumor Activity of CDR404 in HLA-A*02:01 Participants With MAGE-A4 Expressing Solid Tumors",Phase 1,Recruiting,Interventional,Select Advanced Solid Tumors,CDR404,,CDR-Life AG,,42,2024-05-24,2027-12-31,Belgium; Denmark; Italy; Spain; United States,No,https://clinicaltrials.gov/study/NCT06402201
NCT06418204,Complementary Options for Symptom Management In Cancer (COSMIC): Assessing Benefits and Harms of Cannabis and Cannabinoid Use Among a Cohort of Cancer Patients Treated in Community Oncology Clinics,,Recruiting,Observational,Breast Carcinoma; Colorectal Carcinoma; Lung Non-Small Cell Carcinoma; Melanoma; Non-Hodgkin Lymphoma,Non-interventional Study,,Wake Forest University Health Sciences,National Cancer Institute (NCI),2000,2025-01-30,2028-08-05,United States,No,https://clinicaltrials.gov/study/NCT06418204
NCT06439979,Rural Adult and Youth Sun Protection Study - Rural Baseball R01,Not Applicable,Recruiting,Interventional,Melanoma (Skin); Skin Cancer,RAYS Intervention,,University of Utah,Georgetown University; West Virginia University,843,2024-04-08,2030-04-05,United States,No,https://clinicaltrials.gov/study/NCT06439979
NCT06440850,"A Pilot Clinical Trial of Vemurafenib and Cobimetinib as a Redifferentiation Strategy in High-Risk, Radioactive Iodine (RAI) Naïve, BRAFV600E Mutated Differentiated Thyroid Carcinoma Patients Undergoing Initial RAI Therapy",Phase 2,Recruiting,Interventional,Thyroid Gland Follicular Carcinoma; Thyroid Gland Oncocytic Carcinoma; Thyroid Gland Papillary Carcinoma,Biospecimen Collection; Cobimetinib; Computed Tomography; Diagnostic Imaging; I-131 Uptake Test; Iodine I-131; Magnetic Resonance Imaging; Positron Emission Tomography; Recombinant Thyrotropin Alfa; Ultrasound Imaging; Vemurafenib,,City of Hope Medical Center,National Cancer Institute (NCI),21,2024-07-15,2026-11-22,United States,No,https://clinicaltrials.gov/study/NCT06440850
NCT06475989,A Randomized Phase III Study of BRAF-Targeted Therapy vs Cabozantinib in RAI-Refractory Differentiated Thyroid Cancer With BRAF V600Em,Phase 3,Recruiting,Interventional,Refractory Differentiated Thyroid Gland Carcinoma,Biospecimen Collection; Cabozantinib; Computed Tomography; Dabrafenib; Magnetic Resonance Imaging; Questionnaire Administration; Trametinib,,ECOG-ACRIN Cancer Research Group,National Cancer Institute (NCI),264,2024-08-22,2030-09-30,United States,No,https://clinicaltrials.gov/study/NCT06475989
NCT06488365,In Vivo Liquid Biopsy for Early Detection of Metastatic Melanoma,Not Applicable,Recruiting,Interventional,Melanoma; Circulating Tumor Cells; Metastatic Melanoma; Diagnosis,Cytophone,,Cytoastra,,180,2025-02-11,2026-03-31,United States,No,https://clinicaltrials.gov/study/NCT06488365
NCT06582745,"Targeted Approach to Langerhans Cell Histiocytosis (LCH) Using MEK Inhibitor, Trametinib",Phase 2,Recruiting,Interventional,Langerhans Cell Histiocytosis,Trametinib,,Cook Children's Health Care System,,75,2024-06-24,2039-12-05,United States,No,https://clinicaltrials.gov/study/NCT06582745
NCT06599619,A Study of the Effects of Anti-PD1 Adjuvant Checkpoint Blockade Immunotherapy on Features of Atypical/Dysplastic Nevi in Patients With Stage IIB-IIIC Melanoma,,Recruiting,Observational,Melanoma,"Single agent, adjuvant anti-PD1 therapy",,John Kirkwood,Melanoma Research Foundation; VeyTel Inc.,30,2024-11-01,2025-12-05,United States,No,https://clinicaltrials.gov/study/NCT06599619
NCT06608511,Liquid Biomarker Study in Melanoma and Non-Melanoma Skin Cancers,,Recruiting,Observational,"Skin Cancer; Melanoma (Skin Cancer); Basal Cell Carcinoma of Skin; Basal Cell Carcinoma of Skin, Site Unspecified; Cutaneous Squamous Cell Carcinoma (CSCC); Merkel Cell Carcinoma of Skin",Blood draw for the laboratory assessment,,"University of Wisconsin, Madison",National Center for Advancing Translational Sciences (NCATS),20,2024-12-11,2026-12-05,United States,No,https://clinicaltrials.gov/study/NCT06608511
NCT06610682,Feasibility of CSF (Cerebrospinal Fluid) and Plasma ctDNA (Circulating Tumor Deoxyribonucleic) in BRAF (V-raf Murine Sarcoma Viral Oncogene Homolog B1)-Altered Glioma During Treatment With Plixorafenib,Early Phase 1,Recruiting,Interventional,BRAF V600E Mutation,Plixorafenib; Cobicistat 150 MG [Tybost],,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,Fore Biotherapeutics; Ivy Brain Tumor Foundation,15,2025-04-07,2027-06-30,United States,No,https://clinicaltrials.gov/study/NCT06610682
NCT06626516,A Phase I/II Study of Tebentafusp-tebn in Combination With Liver-Directed Therapies for the Treatment of Metastatic Uveal Melanoma,Phase 1/Phase 2,Recruiting,Interventional,Metastatic Uveal Melanoma,Tebentafusp-Tebn; GM-CSF (Sargramostim); BCNU,,Thomas Jefferson University,Sidney Kimmel Cancer Center at Thomas Jefferson University,109,2025-10-15,2032-08-05,United States,No,https://clinicaltrials.gov/study/NCT06626516
NCT06666790,DermaSensor Postmarket Surveillance Study,Not Applicable,Recruiting,Interventional,"Melanoma, Skin",Scan with elastic scattering spectroscopy device to assess risk of malignancy,,"DermaSensor, Inc.",,396,2024-10-08,2027-09-10,United States,No,https://clinicaltrials.gov/study/NCT06666790
NCT06673095,ICEMAN (Intelligent Choice of Excision Margin): A Randomized Controlled Trial of Narrow Excision Versus Wide Excision for Adults With Primary Invasive Cutaneous Melanomas,Not Applicable,Recruiting,Interventional,Clinical Stage IA Cutaneous Melanoma AJCC v8; Clinical Stage IB Cutaneous Melanoma AJCC v8,Biospecimen Collection; Excision; Excision; Survey Administration,,OHSU Knight Cancer Institute,Oregon Health and Science University,1000,2024-12-11,2027-12-31,United States,No,https://clinicaltrials.gov/study/NCT06673095
NCT06683755,Phase I/IIa Dose Finding Study of Triplet Regimen of Relatlimab Ipilimumab and NIvolumab in First Line Therapy of Metastatic Melanoma (TRINITY),Phase 1/Phase 2,Not yet recruiting,Interventional,Melanoma,Nivolumab; Relatlimab; Ipilimumab,,M.D. Anderson Cancer Center,,30,2025-05-01,2032-08-16,United States,No,https://clinicaltrials.gov/study/NCT06683755
NCT06697301,"A Multicenter, Randomized, Double-Blind, Active Comparator-Controlled, Adaptive Phase 2/3 Study to Evaluate the Safety and Efficacy of EIK1001 and Pembrolizumab Versus Placebo and Pembrolizumab as First-Line Therapy in Participants With Advanced Melanoma (TeLuRide-006)",Phase 2/Phase 3,Recruiting,Interventional,Advanced Melanoma,EIK1001; Pembrolizumab (KEYTRUDA® ),,Eikon Therapeutics,Merck Sharp & Dohme LLC,740,2025-05-22,2040-12-05,Australia; Austria; Belgium; Canada; Czechia; Denmark; Finland; France; Germany; Israel; Italy; New Zealand; Norway; Poland; Portugal; Serbia; South Africa; Spain; Sweden; Switzerland; United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT06697301
NCT06708455,Phase 2 Trial of Autologous Rapamycin-Resistant Th1/Tc1 (RAPA-201) Cell Therapy of PD-(L)1 Resistant Malignant Melanoma,Phase 2,Not yet recruiting,Interventional,Malignant Melanoma With Metastasis; Malignant Melanoma; Malignant Melanoma Stage IIIc; Malignant Melanoma Stage IV,RAPA-201 Rapamycin Resistant T Cells; Chemotherapy Prior to RAPA-201 Therapy,,Rapa Therapeutics LLC,,65,2025-11-15,2028-09-30,United States,No,https://clinicaltrials.gov/study/NCT06708455
NCT06712875,A Pilot Study Evaluating the Toxicity and Clinical Benefit of Mitogen-activated Protein Kinase (MAPK) Pathway Inhibition Combined With Programmed Cell Death-1 Checkpoint Blockade (Anti-PD1) for the Treatment of BRAF-altered Pediatric Gliomas,Phase 1/Phase 2,Recruiting,Interventional,Low Grade Glioma; High Grade Glioma,"Trametinib and Nivolumab; Dabrafenib, trametinib, nivolumab",,Ann & Robert H Lurie Children's Hospital of Chicago,,27,2025-04-01,2029-06-05,United States,No,https://clinicaltrials.gov/study/NCT06712875
NCT06745024,Radiation Therapy for High-Risk Asymptomatic Bone Metastases: A Pragmatic Multicenter Randomized Phase 3 Clinical Trial (PREEMPT),Phase 3,Recruiting,Interventional,Metastatic Malignant Neoplasm in the Bone; Metastatic Malignant Solid Neoplasm,Best Practice; Biospecimen Collection; Bone Metastases Treatment; Computed Tomography; Conventional Radiotherapy; Magnetic Resonance Imaging; Patient Observation; Questionnaire Administration; Stereotactic Body Radiation Therapy,,NRG Oncology,,280,2025-04-14,2029-02-01,Canada; United States,No,https://clinicaltrials.gov/study/NCT06745024
NCT06771544,Metronomic Cyclophosphamide With Pembrolizumab in Checkpoint Inhibitor Refractory Melanoma,Phase 2,Recruiting,Interventional,Melanoma; Melanoma Stage III; Melanoma (Skin); Melanoma Stage IV,Pembrolizumab; Cyclophosphamide,,"University of California, Irvine",,14,2024-12-23,2028-12-05,United States,No,https://clinicaltrials.gov/study/NCT06771544
NCT06814496,RAdiation comBined With BIspecific T-Cell Engager in DLL3 Expressing Tumors (RABBIT) Study: A Phase I/II Study of AMG757 / Tarlatamab and Concurrent Radiation Therapy in Tumors With High Prevalence of DLL3,Phase 1/Phase 2,Recruiting,Interventional,Melanoma; Medullary Thyroid Cancer; Sinonasal Undifferentiated Carcinoma; Esthesioneuroblastoma; Bladder Cancer; Testicular Cancer; Glioblastoma Multiforme; Cervical Cancer; Large Cell Neuroendocrine Carcinoma of the Lung; Non Small Cell Lung Cancer; Merkel Cell Carcinoma,Tarlatamab; Concurrent Radiation Therapy; Sequential Radiation therapy,,University of Arizona,Amgen,30,2025-09-08,2030-05-05,United States,No,https://clinicaltrials.gov/study/NCT06814496
NCT06902376,NEO-COMBAT XL: Neoadjuvant and Maintenance XL092 and Cemiplimab in BRAF V600E-wildtype Anaplastic Thyroid Cancer: a Phase 1B Study,Phase 1,Recruiting,Interventional,Anaplastic Thyroid Cancer; Thyroid Cancer; BRAF Mutation-Related Tumors,Cemiplimab; XL092,,UNC Lineberger Comprehensive Cancer Center,Regeneron Pharmaceuticals; Exelixis,12,2025-06-03,2028-08-31,United States,No,https://clinicaltrials.gov/study/NCT06902376
NCT06919809,Efficacy and Safety of X A-DERM™ Microsurfaced Acellular Dermal Matrix (mADM) for Enhancing Wound Healing Following Mohs Micrographic Surgery (MMS),Not Applicable,Recruiting,Interventional,Wound Healing After MMS Surgery; BCC - Basal Cell Carcinoma; SCC - Squamous Cell Carcinoma; Melanoma In Situ,A microsurfaced ADM (acellular dermal matrix),,McGuire Institute,CellTherX,16,2025-08-08,2026-02-28,United States,No,https://clinicaltrials.gov/study/NCT06919809
NCT06946225,"A First-in-human, Open-label Trial to Evaluate the Combination of ACTengine® IMA203 With mRNA-4203 in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma or Synovial Sarcoma Patients (ACTengine® IMA203-102)",Phase 1,Recruiting,Interventional,Cutaneous Melanoma; Synovial Sarcoma,IMA203; mRNA-4203,,"Immatics US, Inc.","ModernaTX, Inc.",15,2025-07-25,2029-08-05,United States,No,https://clinicaltrials.gov/study/NCT06946225
NCT06975293,"Open-label, Non-randomized, Multi-cohort, Phase 1b/2 Trial Investigating the Safety, Tolerability, and Antitumor Activity of STC-15 (a METTL3 Inhibitor) as a Part of Combination Therapy With Toripalimab in Participants With Selected Advanced Cancers",Phase 1/Phase 2,Recruiting,Interventional,Metastatic Non-small Cell Lung Cancer; Metastatic Melanoma; Metastatic Endometrial Cancer; Metastatic Head-and-neck Squamous-cell Carcinoma; Solid Tumor,STC-15 in combination with toripalimab,,STORM Therapeutics LTD,"Coherus Oncology, Inc.",188,2025-05-05,2026-01-29,United States,No,https://clinicaltrials.gov/study/NCT06975293
NCT07040280,A Phase II Double-Blind Trial of Sulforaphane for Therapeutic Prevention of Melanoma in Patients With Multiple Atypical Nevi and a Prior History of Melanoma,Phase 2,Not yet recruiting,Interventional,Melanoma,Sulforaphane (broccoli sprout extract); Placebo; Derma-AI,,Eastern Cooperative Oncology Group,National Institutes of Health (NIH),120,2025-10-31,2029-08-01,United States,No,https://clinicaltrials.gov/study/NCT07040280
NCT07068074,A Randomized Phase III Study of Management of Treatment Naive Primary Melanoma in Elderly Patients,Phase 3,Not yet recruiting,Interventional,Cutaneous Melanoma,Wide local Excision; Sentinel Lymph Node and Wide Local Excision,,Eastern Cooperative Oncology Group,,428,2025-12-12,2031-01-01,United States,No,https://clinicaltrials.gov/study/NCT07068074
NCT07070232,"A Phase I/II, Open-label, Adaptive Two-part Trial to Evaluate the Safety, Efficacy, Optimal Dose and Pharmacokinetics of BNT326 as Monotherapy and in Combination With Cancer Immunotherapies in Participants With Advanced Solid Tumors",Phase 1/Phase 2,Recruiting,Interventional,Advanced Solid Tumor,BNT326; BNT327; Itraconazole; Paroxetine,,BioNTech SE,,550,2025-08-12,2030-02-05,Australia; United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT07070232
